

Implementation of NICE Guidelines and the Quality Standard in Lung Cancer

David Baldwin

Consultant Respiratory Physician

Nottingham University Hospitals


Hon. Professor, University of Nottingham

NICE Fellow

Introduction

- **Overview of implementation**
- **Review of NICE implementation tools**
- **National, regional and local considerations**
- **Pragmatic approach – how can we help?**

Improving Quality and Outcomes



Quality Statements, Measures and Outcomes

- **1. People are made aware of the symptoms and signs of lung cancer through local coordinated public awareness campaigns that result in early presentation.**
 - **Structure**
 - Evidence of local arrangements to ensure that people are made aware of the symptoms and signs of lung cancer through local coordinated public awareness campaigns that result in early presentation.
 - **Process**
 - Proportion of people newly diagnosed with lung cancer who were identified as a result of a local public awareness campaign.
 - **Outcome**
 - a) emergency admissions
 - b) 3-month and 1-year survival
 - c) Public awareness of symptoms and signs of lung cancer.
 - d) Stage at diagnosis.

Early diagnosis

QS1: Public awareness

QS2: Referral for chest X-ray

QS3: Chest X-ray report

Diagnosis and staging

QS6: Investigations

QS7: Tissue diagnosis

Treatment

QS8: Options for curative treatment in patients of borderline fitness

QS9: Access to specialist assessment

QS10: Access to radiotherapy

QS11: Optimal radiotherapy

QS12: Systemic therapy for advanced NSCLC

QS13: Small-cell lung cancer

Supportive and palliative care

QS4: Lung cancer clinical nurse specialist


QS5: Holistic needs assessment

QS15: Palliative interventions

Follow up

QS14: Optimal follow up regime

Drivers to Implementation



Elements of Implementation

- **Guidance based on evidence**
- **Costing**
- **Funding**
- **Education**
- **Behaviour change**
- **Sustainability**
- **Evaluation**

NICE Implementation Tools

- Quality Standard
- Baseline assessment tool [Baseline assess.xls](#)
- Clinical audit tool [GC 121 audit](#)
- Peer Review Manual for Cancer Services
- Costing report
- Costing Template
- Slide set
- Commissioners Guide to End of Life Care

Resource Implications

- **NICE estimate cost of implementation of GL and QS**
- **Will vary according to local practice**



*National Institute for
Health and Clinical Excellence*

Implementation Programme

**NICE support for commissioners and others using the
quality standard on lung cancer**


March 2012

Area of care	Intervention/Activity	National estimated resource impact	Local estimated resource impact (per 100,000 population) ^a
Early diagnosis	Awareness campaigns – may incur cost for media promotion, production of materials and design	No additional resource assumed as national campaign in place.	Local estimation needed.
	X-rays – potential increased cost (from increase in referrals)	Variable. Cannot be estimated nationally	Local estimation needed. £29 unit cost ^b .
Diagnosis and staging	Increased staging tests.	Variable. Cannot be estimated nationally	Local estimation needed
	Histopathology to increase histological confirmation of diagnosis – increased cost	Around £1.17 million (4500 extra samples)	Around £2340 (9 extra samples)
	Tests or diagnostics not taking place unnecessarily – offset cost	Potential saving. Cannot be estimated nationally	Potential saving. Local estimation needed

Treatment	Increased surgery costs for surgical resections.	£10 million (1600 extra resections)	Around £18,000 (3 extra procedures)
	Time multidisciplinary team members would have spent working in other areas – opportunity cost	Variable. Cannot be estimated nationally	Local estimation needed
	Radiotherapy – increased costs	Around £3.5 million (1600 more interventions)	Around £6500 (3 more patients)
	Chemotherapy – increased costs	Around £6.9 million (660 more interventions)	Around £10,500 (1 more intervention)
	Innovation payments to support the use of technology to facilitate better use of multidisciplinary teams	Variable. Cannot be estimated nationally	Local estimation needed

Education

Detail – one size does not fit all



Early diagnosis

QS1: Public awareness

QS2: Referral for chest X-ray

QS3: Chest X-ray report

Diagnosis and staging

QS6: Investigations

QS7: Tissue diagnosis

Treatment

QS8: Options for curative treatment in patients of borderline fitness

QS9: Access to specialist assessment

QS10: Access to radiotherapy

QS11: Optimal radiotherapy

QS12: Systemic therapy for advanced NSCLC

QS13: Small-cell lung cancer

Supportive and palliative care

QS4: Lung cancer clinical nurse specialist

QS5: Holistic needs assessment

QS15: Palliative interventions

Follow up

QS14: Optimal follow up regime

Pragmatics

- **Leads need to sign up to priorities**
- **Support:**
 - Time to educate and encourage
 - Time to develop relationships and trust
- **Time for message to be understood**
- **Reach a point where the GL and QS are the standard of care**

How?

Primary care and commissioning


- **Piles of paper**
 - GL, QS, OIS
- **Regional /Network meetings**
- **Clinical Senates**
- **Local Area Teams**
- **Meet with GP leads on CCG**
- **Meet / talks for GPs**

How?

Secondary care

- **Peer review measures that reflect GL and QS**
- **Regular network meetings**
- **Encourage leads in research and service**
 - **Work according to GL**
 - **Educate colleagues**
 - **Maintain high profile for lung cancer**
 - **Encourage trainees into the subspecialty**

Behaviour Change



Sustainability and Evaluation

- **Reminders of key priorities**
- **Measures, results regularly updated**
- **Promote things that work**
- **Adequate forward planning (resources)**

Conclusion

- **Implementation is essential to improve outcomes**
- **A lot of material available**
- **Drivers are important, but prioritised**
- **Critically dependent on involvement of enthusiastic clinicians and non clinicians**